Program
GSK4347859
A development code.
In GlaxoSmithKline's pipeline, Interferon pathway modulator
. Its studies are mostly in Lupus Erythematosus, Systemic, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 10 open or running | phase 1since Dec 19, 2023 | Dec 19, 2023 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
GSK4347859
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 19, 2023First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT06188507 · 65 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06188507Lupus Erythematosus, Systemic · United Kingdom | 1 | Suspended | Jul 14, 2026 | 65 |
How it is read
Names in the registry
- “GSK4347859”, 1 entry
Codes read as this program: GSK4347859.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.